Respiratory Disease Testing Market

Executive Summary

Respiratory Disease Testing Market was valued at US $8.03 billion in 2021 and is projected to grow at 7.76% CAGR over the forecast period to reach US $12.57 billion by 2027. Respiratory Disease Testing Market represented US $1.11 billion opportunity over 2019-2021 and estimated to create US $4.54 billion opportunity in 2027 over 2021.

Respiratory Disease Testing from Consainsights analyses the Respiratory Disease Testing Market in the Life Sciences industry over the forecast period to 2027.

Respiratory Disease Testing research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Respiratory Disease Testing segmentation includes Test Type, End User and Geography.

Based on the Test Type, the Respiratory Disease Testing analysis covers Imaging Tests, Mechanical Tests, In-vitro Diagnostic Tests.

In Test Type segment, Imaging Tests segment has highest cagr growth of 6.87%.

Based on the End User, the Respiratory Disease Testing analysis covers Hospitals, Diagnostic Centres, Others.

In End User segment, Hospitals segment has highest cagr growth of 6.87%.

Based on the region, the Respiratory Disease Testing analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Beckton Dickinson and Company, Koninklijke Philips N.V., ResMed Inc., Medtronic, Carestream, MG Diagnostic Corporation, Abbott, ThermoFisher Scientific, Biomerieux and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Test Type

Introduction

In 2021, Imaging Tests segment has the highest revenue of US $4.08 billion and is expected to grow at CAGR of 6.87% by 2027 Imaging Tests segment has highest cagr growth of 6.87%.

Imaging Tests

Imaging Tests segment was valued at US $3.52 billion in 2019 and is projected to grow at 6.87% CAGR over the forecast period to reach US $6.39 billion by 2027. Imaging Tests segment represented US $0.57 billion opportunity over 2019-2021 and estimated to create US $2.31 billion opportunity in 2027 over 2021.

Mechanical Tests

Mechanical Tests segment was valued at US $1.97 billion in 2019 and is projected to grow at 6.87% CAGR over the forecast period to reach US $3.57 billion by 2027. Mechanical Tests segment represented US $0.32 billion opportunity over 2019-2021 and estimated to create US $1.29 billion opportunity in 2027 over 2021.

In-vitro Diagnostic Tests

In-vitro Diagnostic Tests segment was valued at US $1.43 billion in 2019 and is projected to grow at 6.87% CAGR over the forecast period to reach US $2.61 billion by 2027. In-vitro Diagnostic Tests segment represented US $0.23 billion opportunity over 2019-2021 and estimated to create US $0.94 billion opportunity in 2027 over 2021.

End User

Introduction

In 2021, Hospitals segment has the highest revenue of US $4.20 billion and is expected to grow at CAGR of 6.87% by 2027 Hospitals segment has highest cagr growth of 6.87%.

Hospitals

Hospitals segment was valued at US $3.61 billion in 2019 and is projected to grow at 6.87% CAGR over the forecast period to reach US $6.57 billion by 2027. Hospitals segment represented US $0.58 billion opportunity over 2019-2021 and estimated to create US $2.37 billion opportunity in 2027 over 2021.

Diagnostic Centres

Diagnostic Centres segment was valued at US $2.46 billion in 2019 and is projected to grow at 6.87% CAGR over the forecast period to reach US $4.48 billion by 2027. Diagnostic Centres segment represented US $0.40 billion opportunity over 2019-2021 and estimated to create US $1.62 billion opportunity in 2027 over 2021.

Others

Others segment was valued at US $0.83 billion in 2019 and is projected to grow at 6.87% CAGR over the forecast period to reach US $1.52 billion by 2027. Others segment represented US $0.13 billion opportunity over 2019-2021 and estimated to create US $0.55 billion opportunity in 2027 over 2021.